Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells

Membrane Estrogen Signaling Enhances Tumorigenesis and Metastatic Potential of Breast Cancer Cells via Estrogen Receptor-α36 (ERα36)

(2012) Reyhaan A. Chaudhri et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Estrogen Receptor-Alpha 36 Mediates Mitogenic Antiestrogen Signaling in ER-Negative Breast Cancer Cells

(2012) XinTian Zhang et al.   PLoS One

Estrogen-independent effects of ER-α36 in ER-negative breast cancer

(2012) Jing Zhang et al.   STEROIDS

Cancer statistics, 2011

(2011) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

A positive cross-regulation of HER2 and ER-α36 controls ALDH1 positive breast cancer cells

(2011) Lianguo Kang et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Unknown

(2011) Yingchun Zhao et al.   MOLECULAR MEDICINE

Macrophage-elicited loss of estrogen receptor-α in breast cancer cells via involvement of MAPK and c-Jun at the ESR1 genomic locus

(2011) F Stossi et al.   ONCOGENE

Mechanisms of Endocrine Resistance in Breast Cancer

(2010) C. Kent Osborne et al.   Annual Review of Medicine

Involvement of Estrogen Receptor Variant ER-α36, Not GPR30, in Nongenomic Estrogen Signaling

(2010) Lianguo Kang et al.   MOLECULAR ENDOCRINOLOGY

A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells

(2010) X T Zhang et al.   ONCOGENE

Biological reprogramming in acquired resistance to endocrine therapy of breast cancer

(2010) H Aguilar et al.   ONCOGENE

ER-α36, a Variant of ER-α, Promotes Tamoxifen Agonist Action in Endometrial Cancer Cells via the MAPK/ERK and PI3K/Akt Pathways

(2010) Sheng-Li Lin et al.   PLoS One

ER-α36, a Novel Variant of ER-α, Mediates Estrogen-Stimulated Proliferation of Endometrial Carcinoma Cells via the PKCδ/ERK Pathway

(2010) Jing-Shan Tong et al.   PLoS One

Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells

(2009) Atanas Ignatov et al.   BREAST CANCER RESEARCH AND TREATMENT

Estrogen receptor-alpha (ER-α) suppresses expression of its variant ER-α36

(2009) Yi Zou et al.   FEBS LETTERS

EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer

(2009) Yang Zhang et al.   INTERNATIONAL JOURNAL OF CANCER

Expression of ER-α36, a Novel Variant of Estrogen Receptor α, and Resistance to Tamoxifen Treatment in Breast Cancer

(2009) Liang Shi et al.   JOURNAL OF CLINICAL ONCOLOGY

A novel variant of ER-alpha, ER-alpha36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells

(2009) Sheng-Li Lin et al.   Reproductive Biology and Endocrinology

Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function

(2008) S. Massarweh et al.   CANCER RESEARCH

Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance

(2008) Grazia Arpino et al.   ENDOCRINE REVIEWS

ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2

(2008) S. Pancholi et al.   ENDOCRINE-RELATED CANCER

Signal Transducer and Activator of Transcription 5b, c-Src, and Epidermal Growth Factor Receptor Signaling Play Integral Roles in Estrogen-Stimulated Proliferation of Estrogen Receptor-Positive Breast Cancer Cells

(2008) Emily M. Fox et al.   MOLECULAR ENDOCRINOLOGY

Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells

(2008) Richard J. Santen et al.   STEROIDS